Cb Therapeutics, Inc.

Beijing Pearl Biotechnology Limited Liability Company

Crown Bioscience Inc. (Taiwan)

Boyu Zhong

Chuan Shih

Deyi Zhang

Hongbin Yuan

Ruihao Zhang

Feng Zhou

Jiaqiang Dong

Shaosong Chu

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer. 

ALK kinase inhibitor, and preparation method and uses thereof

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

Highly selective c-Met inhibitors as anticancer agents

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents

Growing community of inventors

Taicang, China

Boyu Zhong